Safety of hematopoietic stem cell donation in glucose 6 phosphate dehydrogenase-deficient donors.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common RBC enzymatic disorder in humans capable of producing hemolytic events. Recently, concern has been raised about using G6PD-deficienct subjects as hemopoietic stem cell (HSC) donors. In a 10-year period, 101 consecutive HSC donors were submitted to donation procedures for transplantation inside their families in our Center. All donors were tested for G6PD and 19 (19%) turned out to be G6PD-deficient. The donors' safety and the effectiveness of these transplant outcomes were compared with those of the remaining 82 donors. No difference could be observed in any safety parameter between the two groups. No difference was recorded in donors' complications rates, in HSC production, in quantity of growth factor required, in Hb early drop or in Hb recovery. No difference was found in transplant outcome. From this retrospective analysis, we conclude that a G6PD-deficient but otherwise healthy volunteer can be selected as a HSC donor.
Unità Operativa Ematologia e Centro Trapianti Midollo Osseo, Ospedale Oncologico di Riferimento Regionale Armando Businco, Cagliari, Italy.
F
F
Pilo
D
D
Baronciani
C
C
Depau
C
C
Targhetta
M
M
Pani
R
R
Manconi
M G
MG
Fadda
A M
AM
Mamusa
E
E
Angelucci
D000328:Adult; D001782:Blood Donors; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D015331:Cohort Studies; D016238:Cytapheresis; D033001:Directed Tissue Donation; D005192:Family Health; D005260:Female; D000069585:Filgrastim; D005500:Follow-Up Studies; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology; D006401:Hematologic Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007558:Italy; D008297:Male; D008521:Mediterranean Islands; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology; D012189:Retrospective Studies; D014019:Tissue Donors
D006401:Hematologic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim